tirzepatide ruling 2025 FDA Announces End To Compounded By March 19, Meet the Americans who make

Many insurance plans now recognize documented semaglutide failure as a valid reason to approve tirzepatide coverage, particularly for patients with type 2 diabetes or BMI above 30

If you have documented semaglutide failure, your provider can use this as leverage for insurance approval of tirzepatide coverage

If it had truly stopped working, there would be no difference between staying on it and stopping

Similar patterns are expected with retatrutide, as the underlying biological drivers of appetite are being managed by the medication, not permanently altered

Estimation errors of 20 to 30 percent are common and can erase an entire deficit